Biora Therapeutics (NASDAQ: PROG)
Some price data may be temporarily unavailable.
Biora Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Biora Therapeutics Company Info
Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
News & Analysis
Why Shares of Progenity Are Down More Than 11% on Wednesday
The biotech has given investors a bumpy ride this month.
Why Progenity Stock Is Up More Than 34% Tuesday
Shares of the biotech stock rose more than $1.50 per share Tuesday morning.
Why Progenity Stock Was Up More Than 24% Friday
A massive short squeeze saw the biotech stock rise for the second time this week.
Why Progenity Stock Is Soaring on Tuesday
The biotech stock, which has had a volatile year, is a favorite of retail investors because of its potential for a short squeeze.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.